Abstract
Tuberculosis (TB) remains one of the most deadly infectious diseases in the world, killing about 2 million people per year, and mostly affecting the worlds poorest population. The length of current regimens for treatment of TB is long (6-9 months) with a high pill burden. Furthermore, one third of the world population is infected, though asymptomatically, with latent TB and is at risk of developing active TB disease during their lifetime. The current TB epidemic is fuelled by co-infection with HIV, the rise of multidrug-resistant strains, and the ability of the bacterium to become dormant in the lungs and to be reactivated in immunocompromised people. Despite medical advances over the last decades, including the genomic and proteomic revolution, TB still is a highly neglected disease. However, the search for new TB drugs is gaining momentum. Several efforts are underway to develop new drugs, within the academia, the pharmaceutical industry and as public private partnerships. This review will provide a chemical, biological and pharmacological overview of the six drug candidates currently in clinical development. Moxifloxacin (fluoroquinolone), TMC207 (diarylquinoline), PA-824 and OPC-67683 (nitroimidazoles), LL3858 (pyrrole) and SQ109 (ethambutol analogue) will be presented.
Keywords: Infectious disease, Mycobacterium tuberculosis, Moxifloxacin, TMC207, PA824, OPC67683, LL3858, SQ109
Current Bioactive Compounds
Title: New Anti-Tuberculosis Drugs in Clinical Development: An Overview
Volume: 5 Issue: 2
Author(s): Jerome Guillemont, Frederic Lieby-Muller, Nacer Lounis, Wendy Balemans, Anil Koul and Koen Andries
Affiliation:
Keywords: Infectious disease, Mycobacterium tuberculosis, Moxifloxacin, TMC207, PA824, OPC67683, LL3858, SQ109
Abstract: Tuberculosis (TB) remains one of the most deadly infectious diseases in the world, killing about 2 million people per year, and mostly affecting the worlds poorest population. The length of current regimens for treatment of TB is long (6-9 months) with a high pill burden. Furthermore, one third of the world population is infected, though asymptomatically, with latent TB and is at risk of developing active TB disease during their lifetime. The current TB epidemic is fuelled by co-infection with HIV, the rise of multidrug-resistant strains, and the ability of the bacterium to become dormant in the lungs and to be reactivated in immunocompromised people. Despite medical advances over the last decades, including the genomic and proteomic revolution, TB still is a highly neglected disease. However, the search for new TB drugs is gaining momentum. Several efforts are underway to develop new drugs, within the academia, the pharmaceutical industry and as public private partnerships. This review will provide a chemical, biological and pharmacological overview of the six drug candidates currently in clinical development. Moxifloxacin (fluoroquinolone), TMC207 (diarylquinoline), PA-824 and OPC-67683 (nitroimidazoles), LL3858 (pyrrole) and SQ109 (ethambutol analogue) will be presented.
Export Options
About this article
Cite this article as:
Guillemont Jerome, Lieby-Muller Frederic, Lounis Nacer, Balemans Wendy, Koul Anil and Andries Koen, New Anti-Tuberculosis Drugs in Clinical Development: An Overview, Current Bioactive Compounds 2009; 5 (2) . https://dx.doi.org/10.2174/157340709788451975
DOI https://dx.doi.org/10.2174/157340709788451975 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fighting Diabetes: Lessons from Xenotransplantation and Nanomedicine
Current Pharmaceutical Design Repurposing Non-Antimicrobial Drugs and Clinical Molecules to Treat Bacterial Infections
Current Pharmaceutical Design Potential Anticancer Agents. I. Synthesis of Isoxazole Moiety Containing Quinazoline Derivatives and Preliminarily in vitro Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Synthesis of New Cyanopyridine Scaffolds and their Biological Activities
Current Organic Synthesis A Review on Nuclear Imaging as a Promising Modality for Efficient Diagnosis of Tuberculosis
Current Medical Imaging Drug Resistance of Antitubercular Agents at the Genetic Level in Mycobacterium Species: A Road Map to Drug Development for Counteracting the Resistance
Mini-Reviews in Organic Chemistry Cellular and Molecular Mechanisms of Tumor-Induced T-Cell Tolerance
Current Cancer Drug Targets Environmental Factors Contributing to Susceptibility to Tuberculosis
Current Respiratory Medicine Reviews Ultrasound Assisted-synthesis and Biological Evaluation of Piperazinylprop- 1-en-2-yloxy-2H-chromen-2-ones as Cytotoxic Agents
Letters in Drug Design & Discovery Use of Genetically Modified Bacteria to Modulate Adaptive Immunity
Current Gene Therapy General Aspects of Two-Component Regulatory Circuits in Bacteria: Domains, Signals and Roles
Current Protein & Peptide Science Synthesis, Spectroscopic Characterization and Antimicrobial Activities of Benzoxazolone Derivatives
Medicinal Chemistry Cannabinoids and Schizophrenia: Therapeutic Prospects
Current Pharmaceutical Design Importance of Pharmacology Knowledge by Dieticians
Current Nutrition & Food Science Identifying Multiple-target Ligands via Computational Chemogenomics Approaches
Current Topics in Medicinal Chemistry Genetics of the First Seven Proprotein Convertase Enzymes in Health and Disease
Current Genomics Lipoplexes Formulation and Optimisation: In Vitro Transfection Studies Reveal No Correlation with In Vivo Vaccination Studies
Current Drug Delivery Macrocyclic Proteasome Inhibitors
Current Medicinal Chemistry Exploring Interaction of TNF and Orthopoxviral CrmB Protein by Surface Plasmon Resonance and Free Energy Calculation
Protein & Peptide Letters Oral Mucosal Immunization: Recent Advancement and Future Prospects
Current Immunology Reviews (Discontinued)